Entera Bio director buys 20,000 shares at $1.49

Entera Bio Ltd. director transaction: Director Germano J. Geno reported buying 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026.

Rhea-AI Filing Summary

Entera Bio Ltd. director transaction: Director Germano J. Geno reported buying 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026. The shares, each with a par value of NIS 0.0000769, were purchased in a direct ownership transaction at a price of $1.49 per share.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Germano Geno J

Role Director

Bought 20,000 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, par value NIS 0.0000769 per share	20,000	$1.49	$30K

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 0 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entera Bio (ENTX) disclose in this Form 4?

The filing reports that director Germano J. Geno purchased 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026. The transaction involved the company’s ordinary shares with a par value of NIS 0.0000769 per share.

At what price did Entera Bio director Germano J. Geno buy shares?

The director bought the ordinary shares at $1.49 per share. This per-share purchase price applies to the entire block of 20,000 ordinary shares reported in the Form 4, reflecting the cost at which the insider acquired stock in the company.

How many Entera Bio shares were involved in the reported insider purchase?

The Form 4 shows a purchase of 20,000 ordinary shares of Entera Bio Ltd. These shares are described as ordinary shares with a par value of NIS 0.0000769 per share and were acquired in a single reported transaction.

What type of security did Entera Bio’s director acquire in this transaction?

The transaction involved ordinary shares of Entera Bio Ltd., each with a par value of NIS 0.0000769. No derivative securities such as options or warrants are reported as acquired or disposed of in the provided portion of the Form 4.

Was the Entera Bio director’s Form 4 transaction direct or indirect ownership?

The reported purchase of 20,000 ordinary shares is classified as direct ownership. The Form 4 indicates the ownership form as “D” for direct, meaning the shares are held directly by the reporting person rather than through an intermediate entity.

What does transaction code "P" mean in Entera Bio’s Form 4 filing?

The Form 4 uses transaction code “P”, which denotes a purchase of securities in the open market or otherwise. Here it indicates that director Germano J. Geno bought 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 08:45 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Germano Geno J

(Last) (First) (Middle)

KIRYAT HADASSAH, MINRAV BUILDING

5TH FLOOR

(Street)

JERUSALEM L3 9112002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	02/10/2026		P		20,000	A	$1.49	$20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.